The metabolic syndrome (MetS) is a constellation of metabolic abnormalities that includes abdominal obesity, dyslipidemia, elevated blood pressure, and hyperglycemia, all of which are well-documented risk factors for cardiovascular disease (CVD). The National Cholesterol Education Program's Adult Treatment Panel III (ATP III) recommends identification and treatment of this high-risk condition and provides a simple set of diagnostic criteria.
1,2 The MetS components separately increase the risk of diabetes mellitus, CVD, and all-cause mortality, but the full syndrome is associated with risk increases that are greater than the sum of those incurred by each each feature.
3 The prevalence of the MetS is increasing, affecting almost one-fourth of the global adult population, in direct relation to the global epidemic of obesity and diabetes mellitus.
4 As such, the MetS is becoming a major public health problem worldwide.
5